Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, will host a conference call and webcast on August 12, 2025, at 4:30 p.m. ET to discuss its Q2 2025 financial results and provide a corporate update.
Participants can join via telephone using 1-800-267-6316 (domestic) or 1-203-518-9783 (international) with conference ID: VERRICA. The webcast will be available on the company's investor relations website and archived for 90 days.
Verrica Pharmaceuticals (Nasdaq: VRCA), azienda specializzata in terapie dermatologiche, terrà una conference call e una diretta web il 12 agosto 2025 alle 16:30 ET per discutere i risultati finanziari del secondo trimestre 2025 e fornire un aggiornamento aziendale.
I partecipanti potranno collegarsi telefonicamente chiamando il 1-800-267-6316 (nazionale) o il 1-203-518-9783 (internazionale) con ID conferenza: VERRICA. La diretta web sarà disponibile sul sito web per gli investitori della società e archiviata per 90 giorni.
Verrica Pharmaceuticals (Nasdaq: VRCA), una compañía de terapias dermatológicas, realizará una llamada de conferencia y transmisión en línea el 12 de agosto de 2025 a las 4:30 p.m. ET para discutir sus resultados financieros del segundo trimestre de 2025 y ofrecer una actualización corporativa.
Los participantes podrán unirse por teléfono llamando al 1-800-267-6316 (nacional) o al 1-203-518-9783 (internacional) con ID de conferencia: VERRICA. La transmisión estará disponible en el sitio web de relaciones con inversores de la empresa y se archivará durante 90 días.
Verrica Pharmaceuticals (나스닥: VRCA)는 피부 치료제 회사로서 2025년 8월 12일 오후 4시 30분(동부시간)에 2025년 2분기 재무 결과와 회사 현황을 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 진행할 예정입니다.
참여자는 국내 전화 1-800-267-6316 또는 국제 전화 1-203-518-9783로 컨퍼런스 ID: VERRICA를 사용하여 참여할 수 있습니다. 웹캐스트는 회사 투자자 관계 웹사이트에서 시청 가능하며 90일 동안 아카이브됩니다.
Verrica Pharmaceuticals (Nasdaq : VRCA), une société spécialisée dans les traitements dermatologiques, organisera une conférence téléphonique et un webcast le 12 août 2025 à 16h30 ET pour discuter de ses résultats financiers du deuxième trimestre 2025 et fournir une mise à jour d'entreprise.
Les participants peuvent se joindre par téléphone en composant le 1-800-267-6316 (domestique) ou le 1-203-518-9783 (international) avec l'ID de conférence : VERRICA. Le webcast sera disponible sur le site des relations investisseurs de la société et archivé pendant 90 jours.
Verrica Pharmaceuticals (Nasdaq: VRCA), ein Unternehmen für dermatologische Therapien, wird am 12. August 2025 um 16:30 Uhr ET eine Telefonkonferenz und einen Webcast veranstalten, um die Finanzergebnisse des zweiten Quartals 2025 zu besprechen und ein Unternehmensupdate zu geben.
Teilnehmer können sich telefonisch unter 1-800-267-6316 (national) oder 1-203-518-9783 (international) mit der Konferenz-ID: VERRICA einwählen. Der Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein und für 90 Tage archiviert.
- None.
- None.
WEST CHESTER, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, August 12, 2025, to discuss the Company's financial results for the second quarter ending June 30, 2025, and provide a corporate update.
Individuals may participate in the live call via telephone by dialing 1-800-267-6316 (domestic) or 1-203-518-9783 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10 minutes before the start of the call to register.
A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.verrica.com, or by clicking here. A replay of the webcast will be archived on Verrica’s website for 90 days following the event.
About Verrica Pharmaceuticals Inc.
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH® (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH® (VP-102) is also in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com.
FOR MORE INFORMATION, PLEASE CONTACT:
Investors:
John J Kirby
Interim Chief Financial Officer
jkirby@verrica.com
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
FAQ
When is Verrica Pharmaceuticals (VRCA) reporting Q2 2025 earnings?
How can investors access Verrica Pharmaceuticals' Q2 2025 earnings call?
Where can I find the replay of Verrica Pharmaceuticals' Q2 2025 earnings webcast?
What does Verrica Pharmaceuticals (VRCA) do?
